Journal article

Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays.

  • Hoofnagle AN University of Washington, Seattle, WA; ahoof@u.washington.edu apaulovi@fhcrc.org.
  • Whiteaker JR Fred Hutchinson Cancer Research Center, Seattle, WA;
  • Carr SA Broad Institute, Cambridge, MA;
  • Kuhn E Broad Institute, Cambridge, MA;
  • Liu T Pacific Northwest National Laboratory, Richland, WA;
  • Massoni SA New England Peptide, Inc., Gardner, MA;
  • Thomas SN Johns Hopkins University, Baltimore, MD;
  • Townsend RR Washington University, St Louis, MO;
  • Zimmerman LJ Vanderbilt University, Nashville, TN;
  • Boja E National Cancer Institute, Bethesda, MD;
  • Chen J Johns Hopkins University, Baltimore, MD;
  • Crimmins DL Washington University, St Louis, MO;
  • Davies SR Washington University, St Louis, MO;
  • Gao Y Pacific Northwest National Laboratory, Richland, WA;
  • Hiltke TR National Cancer Institute, Bethesda, MD;
  • Ketchum KA ESAC, Inc., Rockville, MD;
  • Kinsinger CR National Cancer Institute, Bethesda, MD;
  • Mesri M National Cancer Institute, Bethesda, MD;
  • Meyer MR Washington University, St Louis, MO;
  • Qian WJ Pacific Northwest National Laboratory, Richland, WA;
  • Schoenherr RM Fred Hutchinson Cancer Research Center, Seattle, WA;
  • Scott MG Washington University, St Louis, MO;
  • Shi T Pacific Northwest National Laboratory, Richland, WA;
  • Whiteley GR Frederick National Laboratory for Cancer Research, Frederick, MD;
  • Wrobel JA University of North Carolina School of Medicine, Chapel Hill, NC;
  • Wu C Pacific Northwest National Laboratory, Richland, WA;
  • Ackermann BL Eli Lilly and Company, Indianapolis, IN;
  • Aebersold R Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland;
  • Barnidge DR Mayo Clinic College of Medicine, Rochester, MN;
  • Bunk DM NIST, Gaithersburg, MD;
  • Clarke N Quest Diagnostics, San Juan Capistrano, CA;
  • Fishman JB 21st Century Biochemicals, Inc., Marlborough, MA;
  • Grant RP Laboratory Corporation of America Holdings, Inc., Burlington, NC;
  • Kusebauch U Institute for Systems Biology, Seattle, WA;
  • Kushnir MM University of Utah and ARUP Laboratories, Salt Lake City, UT;
  • Lowenthal MS NIST, Gaithersburg, MD;
  • Moritz RL Institute for Systems Biology, Seattle, WA;
  • Neubert H Pfizer, Inc., Andover, MA;
  • Patterson SD Gilead Sciences, Inc., Foster City, CA;
  • Rockwood AL University of Utah and ARUP Laboratories, Salt Lake City, UT;
  • Rogers J Thermo Fisher Scientific, Rockford, IL;
  • Singh RJ Mayo Clinic College of Medicine, Rochester, MN;
  • Van Eyk JE Cedars Sinai Medical Center, Los Angeles, CA;
  • Wong SH Wake Forest School of Medicine, Winston-Salem, NC;
  • Zhang S Enanta Pharmaceuticals, Watertown, MA;
  • Chan DW Johns Hopkins University, Baltimore, MD;
  • Chen X University of North Carolina School of Medicine, Chapel Hill, NC;
  • Ellis MJ Baylor College of Medicine, Houston, TX.
  • Liebler DC Vanderbilt University, Nashville, TN;
  • Rodland KD Pacific Northwest National Laboratory, Richland, WA;
  • Rodriguez H National Cancer Institute, Bethesda, MD;
  • Smith RD Pacific Northwest National Laboratory, Richland, WA;
  • Zhang Z Johns Hopkins University, Baltimore, MD;
  • Zhang H Johns Hopkins University, Baltimore, MD;
  • Paulovich AG Fred Hutchinson Cancer Research Center, Seattle, WA; ahoof@u.washington.edu apaulovi@fhcrc.org.
Show more…
  • 2016-01-01
Published in:
  • Clinical chemistry. - 2016
English BACKGROUND
For many years, basic and clinical researchers have taken advantage of the analytical sensitivity and specificity afforded by mass spectrometry in the measurement of proteins. Clinical laboratories are now beginning to deploy these work flows as well. For assays that use proteolysis to generate peptides for protein quantification and characterization, synthetic stable isotope-labeled internal standard peptides are of central importance. No general recommendations are currently available surrounding the use of peptides in protein mass spectrometric assays.


CONTENT
The Clinical Proteomic Tumor Analysis Consortium of the National Cancer Institute has collaborated with clinical laboratorians, peptide manufacturers, metrologists, representatives of the pharmaceutical industry, and other professionals to develop a consensus set of recommendations for peptide procurement, characterization, storage, and handling, as well as approaches to the interpretation of the data generated by mass spectrometric protein assays. Additionally, the importance of carefully characterized reference materials-in particular, peptide standards for the improved concordance of amino acid analysis methods across the industry-is highlighted. The alignment of practices around the use of peptides and the transparency of sample preparation protocols should allow for the harmonization of peptide and protein quantification in research and clinical care.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/64599
Statistics

Document views: 121 File downloads:
  • Full-text: 0